← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일

현재 선택: 1개 · 임상 갱신 필요 1개

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

API CSV14행 · 1개 프로그램
OverviewToxicologyClinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
CGTStandard DatabasestalePhase 3
PF-07055480 (PF-07055480, PF-07055480 (giroctocogene fitelparovec): Recombinant AAV2/6 Human Factor VIII Gene Therapy, giroctocogene fitelparovec)
Pfizer·Hemophilia A
2 trials
Overview
Program
PF-07055480 (giroctocogene fitelparovec): Recombinant AAV2/6 Human Factor VIII Gene Therapy
Overview
Company
Pfizer
Overview
Modality
CGT
Overview
Target
Hemophilia A
Overview
Indication
Hemophilia A
Overview
Phase
PHASE_3
Overview
Status
RECRUITING
Overview
Content status
Standard Database
Overview
Data Confidence
Data Confidence · Medium
Overview
Development Signal
Development Signal · Emerging
Overview
Approval status
Investigational
Toxicology
Major finding
Gene therapy in the treatment of hemophilia A: a systematic review and meta-analysis.. Gene therapy (GT) is an emerging one-time treatment for people with hemophilia A (PwHA). We conducted a systematic review and meta-analysis to evaluate the efficacy, effectiveness, and safety of GT versus factor VIII (FVIII) or emicizumab prophylaxis. Searches of MEDLINE/PubMed, Embase, Cochrane Library, LILACS …
Clinical
Safety signal
Gene therapy in the treatment of hemophilia A: a systematic review and meta-analysis.. Gene therapy (GT) is an emerging one-time treatment for people with hemophilia A (PwHA). We conducted a systematic review and meta-analysis to evaluate the efficacy, effectiveness, and safety of GT versus factor VIII (FVIII) or emicizumab prophylaxis. Searches of MEDLINE/PubMed, Embase, Cochrane Library, LILACS …
Clinical
Program phase
PHASE_3